Brukinsa (zanubrutinib) vs Lunsumio (mosunetuzumab-axgb)

Brukinsa (zanubrutinib) is a small molecule inhibitor specifically designed to target and inhibit Bruton's tyrosine kinase (BTK), which is critical in the proliferation and survival of B-cell cancers; it is often used in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Lunsumio (mosunetuzumab-axgb), on the other hand, is a bispecific T-cell engager antibody that redirects the body's own T-cells to engage and eliminate B-cells, which can be malignant in conditions like follicular lymphoma. The choice between Brukinsa and Lunsumio would depend on the specific type of B-cell malignancy, the patient's overall health, prior treatments, potential side effects, and the recommendations of the treating oncologist.

Difference between Brukinsa and Lunsumio

Metric	Brukinsa (zanubrutinib)	Lunsumio (mosunetuzumab-axgb)
Generic name	Zanubrutinib	Mosunetuzumab-axgb
Indications	Mantle cell lymphoma, Waldenström's macroglobulinemia	Follicular lymphoma
Mechanism of action	Bruton's tyrosine kinase inhibitor	Bispecific T-cell engager antibody
Brand names	Brukinsa	Lunsumio
Administrative route	Oral	Intravenous
Side effects	Neutropenia, thrombocytopenia, anemia, diarrhea, cough	Cytokine release syndrome, hypotension, fatigue, fever, headache
Contraindications	Hypersensitivity to zanubrutinib	Hypersensitivity to mosunetuzumab-axgb
Drug class	Antineoplastic agent	Antineoplastic agent
Manufacturer	BeiGene	Genentech, Inc.

Efficacy

Brukinsa (Zanubrutinib) Efficacy in Treating Lymphoma

Brukinsa (zanubrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor that has shown efficacy in the treatment of various types of lymphoma, including mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia. In clinical trials, zanubrutinib has demonstrated high response rates in patients with relapsed or refractory MCL. The overall response rate (ORR) in these studies was significant, with many patients achieving a complete or partial response to the therapy. The duration of response (DOR) and progression-free survival (PFS) were also notable, indicating that zanubrutinib can provide a meaningful clinical benefit in this patient population.

Furthermore, zanubrutinib has been compared to other BTK inhibitors and has shown a favorable safety and tolerability profile, which is an important consideration in the chronic management of lymphoma. Its efficacy in treating lymphoma has led to its approval by regulatory agencies for certain indications, providing an additional therapeutic option for patients with B-cell malignancies.

Lunsumio (Mosunetuzumab-axgb) Efficacy in Treating Lymphoma

Lunsumio (mosunetuzumab-axgb) is a bispecific T-cell engager antibody that targets both CD20 on B cells and CD3 on T cells, thereby redirecting T cells to engage and eliminate B cells. This novel mechanism of action has shown promise in the treatment of non-Hodgkin lymphoma (NHL), including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). In clinical trials, mosunetuzumab-axgb has demonstrated significant efficacy in patients with relapsed or refractory NHL, with many patients achieving complete responses.

The efficacy of mosunetuzumab-axgb has been particularly noteworthy in heavily pretreated patient populations, where limited treatment options exist. The ORR and complete response rates in these studies suggest that mosunetuzumab-axgb could represent a breakthrough in the treatment of certain types of B-cell lymphomas. Additionally, the duration of these responses has been encouraging, with a number of patients maintaining response over an extended period. These results support the continued development and potential future approval of mosunetuzumab-axgb for the treatment of lymphoma.

Regulatory Agency Approvals

Brukinsa

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Lunsumio

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Brukinsa or Lunsumio today

If Brukinsa or Lunsumio are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Brukinsa

Buy Lunsumio

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: